Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 (Ipilimumab) in Metastatic Hormone-Refractory Prostate Cancer
NCT00323882Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2006
- Primary completion
- Sep 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in prostate cancer (PCa), sponsored by Bristol Myers Squibb. Started Jan 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00323882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323882.